SG/CALL/EDWARDS LIFESCIENCES/70/0.1/20.09.24 | Delayed Deutsche Boerse AG 07:22:28 07/06/2024 pm IST | ||
| 1.78 EUR | -3.26% |
|
| Current month | +5.75% | ||
| 1 month | +1.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 1.78 | -3.26% |
| 06/24/06 | 1.84 | +2.79% |
| 05/24/05 | 1.79 | -1.65% |
| 04/24/04 | 1.82 | -2.67% |
| 03/24/03 | 1.87 | +7.47% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 07:22 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SU2MAG |
| ISIN | DE000SU2MAG1 |
| Date issued | 22/11/2023 |
| Strike | 70 $ |
| Maturity | 20/09/2024 (105 Days) |
| Parity | 10 : 1 |
| Emission price | 1.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.84 € |
|---|---|
| Lowest since issue | 0.95 € |
| Spread | 0.01 € |
| Spread % | 0.55% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.68
USD
Average target price
96.31
USD
Spread / Average Target
+9.84%
- Stock Market
- Warrants
- Warrant
